Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Anavex Life Sciences Corporation | AVXL | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 8.01 | 03:08:46 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 8.01 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 4.90 - 11.925 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 8.01 | USD |
Anavex Life Sciences (AVXL) Options Flow Summary
Anavex Life Sciences Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 657.51M | 82.09M | - | 0 | -47.51M | -0.58 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Anavex Life Sciences News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AVXL Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 7.27 | 8.32 | 7.01 | 7.78 | 1,077,742 | 0.74 | 10.18% |
| 1 Month | 5.98 | 8.32 | 5.47 | 6.79 | 1,171,166 | 2.03 | 33.95% |
| 3 Months | 7.98 | 8.3899 | 4.90 | 6.50 | 1,049,724 | 0.03 | 0.38% |
| 6 Months | 9.07 | 10.17 | 4.90 | 7.43 | 953,493 | -1.06 | -11.69% |
| 1 Year | 8.38 | 11.925 | 4.90 | 8.44 | 1,048,085 | -0.37 | -4.42% |
| 3 Years | 4.90 | 31.50 | 4.638 | 13.07 | 1,479,893 | 3.11 | 63.47% |
| 5 Years | 2.21 | 31.50 | 1.25 | 10.88 | 1,160,336 | 5.80 | 262.44% |
Anavex Life Sciences Description
| Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2. |
